BioGaia has entered into an exclusive agreement for its probiotic drops with Nestlé in Mexico

BioGaia has signed an agreement with Nestlé Mexico, for the exclusive rights to
sell BioGaia’s probiotic drops in Mexico from 2013. The product will be sold
under the BioGaia brand.
This is the second contract with Nestlé since BioGaia’s sale to Nestlé of
license rights to use BioGaia’s patented Lactobacillus reuteri Protectis in
infant formula, announced in February 2012, at which time the two companies
entered into a number of development and option agreements. The first contract,
signed in June, was with Nestlé’s Gerber division in the United States and
included the probiotic drops and oral rehydration solution. As the oil drops
already are on the market in Mexico, this is a part of BioGaia’s on-going change
of distributor programme.

The BioGaia ProTectis baby drops contains BioGaia’s patented and well-researched
probiotic strain Lactobacillus reuteri Protectis. Today the drops are available
in more than 50 countries.

“We are pleased with the agreement with Nestlé Mexico. With Nestlé’s sales force
of more than 100 sales representatives visiting pediatricians and their
marketing capacity we are confident that sales will grow faster in this very
important market”, says Peter Rothschild, Chief Executive Officer, BioGaia.

Latest press releases from BioGaia
2012-10-23  BioGaia AB Interim report 1 January-30 September 2012
2012-10-15  BioGaia’s signs probiotic safe and effective in premature infants
2012-10-12  BioGaia signs exclusive distribution agreement for its probiotic
drops and tablets in Pakistan

BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 22 November 2012,
11:00 am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com